YU42094B - Process for obtaining new morpnoline compounds - Google Patents

Process for obtaining new morpnoline compounds

Info

Publication number
YU42094B
YU42094B YU96/79A YU9679A YU42094B YU 42094 B YU42094 B YU 42094B YU 96/79 A YU96/79 A YU 96/79A YU 9679 A YU9679 A YU 9679A YU 42094 B YU42094 B YU 42094B
Authority
YU
Yugoslavia
Prior art keywords
compounds
morpnoline
obtaining new
morpholine
phenoxy
Prior art date
Application number
YU96/79A
Other languages
English (en)
Other versions
YU9679A (en
Inventor
P Melloni
Torre A Della
G C Carniel
A Rossi
Original Assignee
Erba Farmitalia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1944978A external-priority patent/IT1093255B/it
Priority claimed from IT1945078A external-priority patent/IT1111676B/it
Priority claimed from IT3053378A external-priority patent/IT1160301B/it
Priority claimed from IT3053478A external-priority patent/IT1160302B/it
Priority claimed from IT30535/78A external-priority patent/IT1101724B/it
Application filed by Erba Farmitalia filed Critical Erba Farmitalia
Priority to SI7910096A priority Critical patent/SI7910096A8/sl
Publication of YU9679A publication Critical patent/YU9679A/xx
Publication of YU42094B publication Critical patent/YU42094B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/32Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/16Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C07D265/33Two oxygen atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
YU96/79A 1978-01-20 1979-01-17 Process for obtaining new morpnoline compounds YU42094B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI7910096A SI7910096A8 (sl) 1978-01-20 1979-01-17 Postopek za pripravo novih morfolinskih spojin

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT1944978A IT1093255B (it) 1978-01-20 1978-01-20 Derivati fenossialcanolaminici
IT1945078A IT1111676B (it) 1978-01-20 1978-01-20 Derivati della 2-fenossimetil-morfolina
IT3053378A IT1160301B (it) 1978-12-05 1978-12-05 Derivati fenossialcanolaminici
IT3053478A IT1160302B (it) 1978-12-05 1978-12-05 Derivati della 2-fenossimentil-morfolina
IT30535/78A IT1101724B (it) 1978-12-05 1978-12-05 Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione

Publications (2)

Publication Number Publication Date
YU9679A YU9679A (en) 1983-12-31
YU42094B true YU42094B (en) 1988-04-30

Family

ID=27517788

Family Applications (1)

Application Number Title Priority Date Filing Date
YU96/79A YU42094B (en) 1978-01-20 1979-01-17 Process for obtaining new morpnoline compounds

Country Status (24)

Country Link
US (2) US4229449A (da)
JP (1) JPS54148739A (da)
AT (1) AT371813B (da)
AU (1) AU525954B2 (da)
BG (1) BG61056B2 (da)
CA (1) CA1128942A (da)
CH (1) CH650245A5 (da)
CS (1) CS413391A3 (da)
CY (1) CY1172A (da)
DE (2) DE2901032C2 (da)
DK (1) DK156565C (da)
FI (1) FI71135C (da)
FR (2) FR2442839A1 (da)
GB (1) GB2014981B (da)
HK (1) HK5783A (da)
IE (1) IE47727B1 (da)
IL (1) IL56369A (da)
KE (1) KE3243A (da)
MY (1) MY8400018A (da)
NO (1) NO146953C (da)
NZ (1) NZ189418A (da)
SE (1) SE446727B (da)
SI (1) SI7910096A8 (da)
YU (1) YU42094B (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226523A (en) * 1978-11-17 1980-10-07 Energy Conversion Devices, Inc. Imaging device
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2162517B (en) * 1984-08-01 1988-04-27 Erba Farmitalia Process for the preparation of 3-substituted derivatives of 1-amino-2-hydroxy-propane
DE3546929B4 (de) * 1984-08-02 2006-02-09 Pharmacia Italia S.P.A. 1,2-substituierte Derivate von 3-Phenoxy-3-Phenylpropan
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
GB8823405D0 (en) * 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
CA2304112A1 (en) * 1997-09-23 1999-04-01 John Harrison Heiligenstein Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
CA2321157A1 (en) 1998-04-09 1999-10-21 Pharmacia & Upjohn Company New treatments for nervous disorders
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
JP2002533430A (ja) * 1998-12-29 2002-10-08 ファルマシア・アンド・アップジョン・カンパニー アリールエーテルの調製方法
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
DK1493442T3 (da) * 1999-07-01 2005-12-19 Pharmacia & Upjohn Co Llc Reboxetin til behandling af perifer neuropati
CN1660109A (zh) * 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
EP1333835A1 (en) * 2000-10-31 2003-08-13 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
ES2287338T3 (es) * 2001-11-30 2007-12-16 Eli Lilly And Company Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics.
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
BR0313411A (pt) * 2002-08-14 2005-06-28 Pharmacia & Upjohn Co Llc Uso de reboxetina para o tratamento de ondas de calor
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
EP1587782A1 (en) * 2002-11-05 2005-10-26 Eli Lilly and Company 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
BRPI0409492A (pt) * 2003-04-18 2006-05-02 Pharmacia & Up John Company Ll terapias de combinação
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
BRPI0414347A (pt) * 2003-09-12 2006-11-07 Warner Lambert Co associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
EP1663398B1 (en) 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7402698B2 (en) * 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
CA2556063A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
MXPA06012505A (es) * 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
JP2008538572A (ja) 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
EP1904843A2 (en) 2005-07-08 2008-04-02 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
PT2076508E (pt) 2006-10-18 2011-03-07 Pfizer Prod Inc Compostos de ureia de éter biarílico
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
WO2010011811A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
PT2358674E (pt) 2008-11-14 2013-03-05 Theravance Inc Processo de preparação de compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
CN105254552A (zh) * 2009-07-13 2016-01-20 施万生物制药研发Ip有限责任公司 3-苯氧基甲基吡咯烷化合物
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
EP2627630B1 (en) 2010-10-11 2014-12-31 Theravance Biopharma R&D IP, LLC Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
BE759013R (fr) * 1969-11-17 1971-05-17 Ici Ltd Derives de la
GB1382526A (en) * 1972-08-11 1975-02-05 Ici Ltd Morpholine derivatives
GB1412546A (en) * 1973-08-08 1975-11-05 Ici Ltd Morpholine derivatives
GB1427097A (en) * 1973-10-18 1976-03-03 Ici Ltd Optically-active morpholine derivatives
GB1469410A (en) * 1973-12-17 1977-04-06 Christiaens Sa A Benzodioxole derivatives
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1576216A (en) * 1975-01-29 1980-10-01 Yamanouchi Pharma Co Ltd 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them
CA1064927A (en) * 1975-01-29 1979-10-23 Yuji Kawashima Process of producing 2-(indenyloxymethyl) morpholine derivatives
CA1085841A (en) * 1976-05-19 1980-09-16 Jean-Marie Ferland Aryloxy proplamines, their preparation and use thereof

Also Published As

Publication number Publication date
DE2901032C2 (de) 1996-05-30
NO790205L (no) 1979-07-23
KE3243A (en) 1982-12-03
FR2442839B1 (da) 1984-07-27
FR2430412A1 (fr) 1980-02-01
IE790107L (en) 1979-07-20
IL56369A0 (en) 1979-03-12
NO146953B (no) 1982-09-27
ATA40679A (de) 1982-12-15
FI71135C (fi) 1986-11-24
US4229449A (en) 1980-10-21
IL56369A (en) 1984-05-31
US4271160A (en) 1981-06-02
AU525954B2 (en) 1982-12-09
CH650245A5 (de) 1985-07-15
YU9679A (en) 1983-12-31
FR2442839A1 (fr) 1980-06-27
JPS6331455B2 (da) 1988-06-23
SE446727B (sv) 1986-10-06
GB2014981A (en) 1979-09-05
BG61056B2 (bg) 1996-09-30
AU4332779A (en) 1979-07-26
FR2430412B1 (fr) 1987-06-26
MY8400018A (en) 1984-12-31
FI71135B (fi) 1986-08-14
DE2901032A1 (de) 1979-08-02
SE7900498L (sv) 1979-07-21
AT371813B (de) 1983-08-10
NO146953C (no) 1983-01-05
IE47727B1 (en) 1984-05-30
DK22679A (da) 1979-07-21
CA1128942A (en) 1982-08-03
FI790177A (fi) 1979-07-21
HK5783A (en) 1983-02-08
JPS54148739A (en) 1979-11-21
DK156565C (da) 1990-02-05
NZ189418A (en) 1981-03-16
CY1172A (en) 1983-06-10
SI7910096A8 (sl) 1996-10-31
DK156565B (da) 1989-09-11
DE19875005I2 (de) 2002-10-24
GB2014981B (en) 1982-08-11
CS413391A3 (en) 1992-05-13

Similar Documents

Publication Publication Date Title
YU9679A (en) Process for obtaining new morpholine compounds
NL990037I1 (nl) Een isoxyzoolderivaat, werkwijze voor zijn bereiding en deze verbinding bevattende middelen.
ES520195A0 (es) Procedimiento para preparar nuevos derivados de 3-ceto- 4,9,19-nor-esteroides.
ES527776A0 (es) Procedimiento de preparacion de derivados de 1,4-dihidropiridinas.
ES511260A0 (es) Procedimiento para la obtencion de nuevos derivados de omega-ciano-1, omega-difenil-aza-alcano.
YU268582A (en) Process for obtaining new substituted benzamides
DE3275184D1 (de) 2-(trisubstituted phenylimino)-imidazolines
AU5385479A (en) Cyanamides
ES510504A0 (es) Procedimiento para la obtencion de azoles 2,4,5-trisustituidos.
IT8023315A0 (it) 2-(3,4,5-trimetossifenil)-tiazoli 4,5-bisostituiti e procedimento per la loro preparazione.
ES482438A0 (es) Procedimiento para la preparacion de nuevos derivados de 2-(4-aminopiperidino)-3,4-dihidroquinoleina.
ES485933A0 (es) Procedimiento para preparar compuesto 2-imino-1, 3-ditio-he-terociclicos sustituidos.
ES510302A0 (es) Procedimiento para la preparacion de 4-(3-trifluormetilfenil)-1,2,3,6-tetrahidropiridinas.
IT1113373B (it) Derivati del 1,5-dimetilbiciclo(3.2.1.)-ottano,preparazione di questi composti e loro impiego come composti per profumi
ES520201A0 (es) Procedimiento para la obtencion de derivados de 1,4-dihidropiridina.
MX159206A (es) Procedimiento para preparar derivados de 20,21 dinoreburnamenina
IT8319615A0 (it) Macchina rettificatrice, particolarmente per la bombatura di cilindri.
ES8105287A1 (es) Procedimiento para preparar un derivado de piperidina
IT8122397A0 (it) Derivati di 3-aril- e 3-eterociclil-2,3-diidro-1,4-benzossazina.
FI824155A0 (fi) Foerfarande foer framstaellning av 3,7a-diazacyklohepta/j,k/fluoren
NO153657C (no) Fremgangsmaate for fremstilling av hoeykvalitets, rent ferromangan.
JPS5253842A (en) Preparing aminopropanol derivative
ES484069A0 (es) Procedimiento para preparar nuevos derivados de oxadiazolin-1,3,4-ona-5.
FI77023B (fi) Foerfarande foer framstaellning av 1-alkyl- eller 1,4-dialkyl-1h-pyrrol-2-aettiksyraestrar.
JPS5223935A (en) Paper feed means for the copying machine